Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2162-3619
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia ; volume:6 ; number:1 ; day:14 ; month:4 ; year:2017 ; pages:1-7 ; date:12.2017
Experimental hematology & oncology ; 6, Heft 1 (14.4.2017), 1-7, 12.2017
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Wei, Guoqing
- Beteiligte Personen und Organisationen
-
Ding, Lijuan
Wang, Jiasheng
Hu, Yongxian
Huang, He
SpringerLink (Online service)
- DOI
-
10.1186/s40164-017-0070-9
- URN
-
urn:nbn:de:1111-201704309213
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wei, Guoqing
- Ding, Lijuan
- Wang, Jiasheng
- Hu, Yongxian
- Huang, He
- SpringerLink (Online service)
Ähnliche Objekte (12)
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Infections in hematologic malignancy patients treated by CD19 chimeric antigen receptor T‐cell therapy
HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden
The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies
Engineering better chimeric antigen receptor T cells
Special issue: CAR‐T cell therapy for hematological malignancies
Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives
Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
Mesenchymal stem cells in rabbit meniscus and bone marrow exhibit a similar feature but a heterogeneous multi-differentiation potential: superiority of meniscus as a cell source for meniscus repair
An in vivo study of the best light emitting diode (LED) systems for cut chrysanthemums
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Infections in hematologic malignancy patients treated by CD19 chimeric antigen receptor T‐cell therapy
HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden
The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies
Engineering better chimeric antigen receptor T cells
Special issue: CAR‐T cell therapy for hematological malignancies
Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives
Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
Mesenchymal stem cells in rabbit meniscus and bone marrow exhibit a similar feature but a heterogeneous multi-differentiation potential: superiority of meniscus as a cell source for meniscus repair
An in vivo study of the best light emitting diode (LED) systems for cut chrysanthemums
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Infections in hematologic malignancy patients treated by CD19 chimeric antigen receptor T‐cell therapy
HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden
The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies
Engineering better chimeric antigen receptor T cells
Special issue: CAR‐T cell therapy for hematological malignancies
Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives
Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
Mesenchymal stem cells in rabbit meniscus and bone marrow exhibit a similar feature but a heterogeneous multi-differentiation potential: superiority of meniscus as a cell source for meniscus repair